Event Abstract Back to Event A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products Brian Edwards1*, Bernard Bégaud2, Esther Daemen3, Ioannis Dokas4, Jonathan Fishbein5, Howard Greenberg6, Alan Hochberg7, Herve Le Louet8, Jytte Lyndvig9, Nataliya Mogles10, Kathyryn Owen11, Christine Prendergast12, Martin Rejzek13, Sofia Trantza14, David Webb15, Mathew Whalen16 and Simon Whiteley17 1 ACRES, Product Safety Culture Initiative, UK 2 Universite de Bordeaux, Pharmacology, France 3 Trium Clinical Consulting NV, Clinical Research, Belgium 4 Democirtus University of Thrace, Systems Engimeering, Greece 5 PRA Health Sciences, Medical Services, United States 6 Thomas Jefferson University, Clinical Pharmacology, United States 7 F. Hoffman-La Roche Ltd, Drug Safety, Switzerland 8 Publique Hôpitaux de Paris, Pharmacovigilance, France 9 Danish Medicines Agency (retired), CEO (retired), Denmark 10 University of Bath, Computer Sciences, UK 11 Owen Clinical Consulting Ltd, Consultant, UK 12 Quintiles IMS, Pharmacovigilance, Ireland 13 Zurich University of Applied Sciences, Switzerland 14 National Medicines Agency (EOF);, Pharmacovigilance, Greece 15 University of Edinburgh, Clinical Pharmacology, UK 16 Alliance for Clinical Research Excellence and Safety (Acres), United States 17 Whiteley Aerospace Safety Engineering & Management Ltd; , UK Purpose: We believe that repetition of potentially preventable and adverse outcomes during clinical research through not identifying and acting upon all systematic vulnerabilities is a situation that needs urgent change and that time for action is now. Methods: A joint assessment has been performed by individual pharmacology and pharmaceutical professionals acting in their own capacity including members of the Alliance for Clinical Research Excellence and Safety and the International Society of Pharmacovigilance. Results: By building on the extensive pharmacological and regulatory investigations that already take place, we are calling for a fuller and more robust systems-based approach to the independent investigation of clinical research when serious incidents of harm occur starting with first-into-human trials. To complement existing activities and regulations, we propose an additional approach blending evidence derived from pharmacological and organisational science which addresses human factors and transparency to enhance organisational learning and continuous improvement (1, 2). Conclusions: This systems approach should be seen as an additional way to understand how problems occur and how they might be prevented in the future. Approaches based on applying systems theory and human factors are much more likely to improve objectivity and transparency leading to better systems design and enhanced trust in clinical research.
Read full abstract